EUCTR2009-017669-44-PL进行中（未招募）不适用
A study of the Effects of Inhaled Fliticasone Furotate/GW642444 versus Placebo on HPA Axis of Adolescent and Adult Asthmatics.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 185
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Type of Subject: Outpatient and able to complete two overnight domiciled clinic
- •2. Age =18 to =65.
- •3. Gender: Male or Eligible Female
- •To be eligible for entry into the study, females of childbearing potential must commit
- •to consistent and correct use of an acceptable method of birth control, as defined by
- •the following:
- •Male partner who is sterile prior to the female subject’s entry into the study and
- •is the sole sexual partner for that female subject
- •Implants of levonorgestrel
- •Injectable progestogen
- •Oral contraceptive (either combined estrogen/progestin or progestin only)
- •Estrogenic vaginal ring
- •Percutaneous contraceptive patches
- •Any intrauterine device (IUD) or intrauterine system (IUS) with a documented
- •failure rate of less than 1% per year.
- •Double barrier method – condom and an occlusive cap (diaphragm or
- •cervical/vault caps) with a vaginal spermicidal agent
- •(foam/gel/film/cream/suppository)
- •Abstinence: Females of childbearing potential who are not sexually active must
- •commit to complete abstinence from intercourse throughout the clinical trial and
- •for a period after the trial to account for elimination of the drug (minimum of six
- •Female subjects should not be enrolled if they are pregnant, lactating or plan to
- •become pregnant during the time of study participation. A serum pregnancy test will
- •be required on all females of childbearing potential at Visit 1.
- •4. Asthma Diagnosis: A history of asthma as defined by the National Institutes of
- •Health [NIH, 2007] for at least 12 weeks prior to Visit 1.
- •5. Severity of Disease: A best FEV1 of =50% of the predicted normal value during the
- •Visit 1 screening visit. Predicted values will be based upon NHANES III.
- •[Hankinson, 1999]. Note: If a subject is recorded as having Hispanic or Latino
- •ethnicity then the Mexican-American equations will be used (irrespective of race). If
- •a subject and is recorded as being of African American/African heritage race, then the
- •African-American equations will be used. Otherwise the Caucasian equations will be
- •6. Reversibility of Disease: Demonstrated a = 12% and =200mL reversibility of FEV1
- •within approximately 10 to 40 minutes following 2 to 4 inhalations of
- •albuterol/salbutamol inhalation aerosol (if required, spacers are permitted for
- •reversibility testing only) or one nebulized albuterol/salbutamol solution during the
- •screening period or historical documentation of same FEV1 reversibility within 12
- •months prior to screening or a positive methacholine challenge test within 12 months prior to screening. A positive response to a methacholine challenge is defined as a 20% decrease in response to methacholine (PC20) of <8 mg/ml.
- •7. Short-acting Beta2-Agonists: All subjects must be able to replace their current
- •short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for
- •use as needed for the duration of the study. The use of spacer devices with metered
- •dose inhaler (MDI) or nebulized albuterol/salbutamol will not be allowed during the
- •study with the exception of their use during reversibility testing at Visit 1. Subjects
- •must be able to withhold all inhaled short-acting beta sympathomimetic
- •bronchodilators for at least 6 hours prior to study visits.
- •8. Informed Consent: All subjects must be able and willing to give written informed
- •consent to take part in the study.
- •9. Compliance: Subjects must be judged by the investigator as able to comply with
- •study procedures and completion of the d
排除标准
- •1. History of Life-threatening Asthma: Defined for this protocol as an asthma
- •episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures within 5 years prior to Visit 1.
- •2. Concurrent Respiratory Disease: A subject must not have current evidence of
- •pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease,
- •bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive
- •pulmonary disease, or other respiratory abnormalities other than asthma.
- •3. Respiratory Infection: Culture-documented or suspected bacterial or viral infection
- •of the upper or lower respiratory tract, sinus, or middle ear - view protiocol for further information
- •4. Asthma Exacerbation: Any asthma exacerbation requiring systemic corticosteroids
- •within 12weeks of Visit 1. A subject must not have had any overnight hospitalization for asthma within 6 months prior to Visit 1.
- •5. Concurrent Diseases/Abnormalities: Other Concurrent Diseases/Abnormalities: A subject must not have any clinically significant, uncontrolled condition or disease - view protocol for further information.
- •6. Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she
- •has clinical visual evidence of oral candidiasis at Visit 1.
- •7. Investigational Medications: Use of any investigational drug within 30 days prior to
- •8. Previous Study Participation: A subject may not have previously been randomized
- •to treatment in a Phase III fluticasone furoate/GW642444 combination product study
- •(i.e., HZA106825, HZA106827, HZA106829, HZA106837, HZA106839,
- •HZA113091).
- •9. Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity
- •to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic
- •corticosteroid therapy - view protocol for further information.
- •10. Milk Protein Allergy: History of severe milk protein allergy.
- •11. Immunosuppressive Medications: A subject must not be using, or require use, of
- •immunosuppressive medications during the study.
- •12. Concomitant Medications: Use of prescription or over-the-counter medications that would significantly affect the course of asthma - view protocol for further information.
- •13. Systemic/Oral/Depot Corticosteroid: Administration of systemic, oral or depot corticosteroids within 12 weeks prior to Visit 1 and during the study is prohibited.
- •14. Inhaled Corticosteroid Use: Use of an inhaled corticosteroid during the 4 weeks
- •prior to Visit 1 and during the study is prohibited.
- •15. Intranasal Corticosteroids: Use is prohibitedd starting one day prior to Visit 1 and during the study..
- •16. Potent Cytochrome P450 3A4 (CYP3A4) inhibitors: A subject is not eligible if
- •he/she is receiving potent CYP34A inhibitor within 4 weeks of Visit 1 and during the
- •study (e.g., ritonavir, ketoconazole, itraconzole).
- •17. Long-acting beta2-agonists: Use is prohibited for 4 weeks prior to Visit 1 and
- •during the study.
- •18. Extended-release short-acting beta2-agonists: Use is prohibited for the period of the prescribed dosing interval prior to the screening visit for the duration of the study.
- •19. Attendance: A subject will not be eligible if he/she or his/her parent or legal
- •guardian has any infirmity, disability, or resides in a geographical location which
- •seems likely (in the opinion of the Investigator) to impair compliance with any aspect
- •of this study protocol, scheduled visits to the study center, non-compliance with
- •investigational product, or procedu
研究者
相似试验
进行中（未招募）
不适用
A 6-month study to assess the safety and benefit of inhaled fluticasone propionate/salmeterol combination compared with inhaled fluticasone propionate in the treatment of adolescents (12 years and over) and adults with asthma.AsthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2011-001644-29-CZGlaxoSmithKline Research & Development Limited11,664
进行中（未招募）
不适用
The Pharmacokinetics of Inhaled Fluticasone Propionate delivered as Monodisperse Aerosols - Pharmacokinetics of inhaled monodisperse Fluticasone PropionateHealthy volunteers and mild to moderate asthmaMedDRA version: 9.1Level: LLTClassification code 10052996Term: Inhalation therapyMedDRA version: 9.1Level: LLTClassification code 10053349Term: Pharmacokinetic studyMedDRA version: 9.1Level: PTClassification code 10003553Term: AsthmaEUCTR2008-002139-34-GBImperial College London30
已完成
4 期
Comparative efficacy of daily inhaled fluticasone propionate and episodic inhaled combined salmeterol/fluticasone propionate in children with recurrent wheezingrecurrent wheezingEfficacy,Daily,Episodic,Inhaled corticosteroids,Recurrent wheezingTCTR20180614002Queen Sirikit National Institute of Child Health72
已完成
1 期
Effects of fluticasone nasal spray on clinical symptoms and serum IgENasal polypIRCT20140519017756N40Mashhad University of Medical Sciences34
已完成
2 期
The Effect of Intratracheal Furosemide, Salbutamol, or a Mixture of Both with Surfactant on Clinical Course of Neonatal Respiratory Distress SyndromeRespiratory Distress Syndrome.certain conditions originating in the perinatal periodP00-P96IRCT2014072714215N1Ahvaz Jundishapur University of Medical Sciences48